# US 2015/0104457 A1 · Il-17 antagonist antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104457 A1
- Document ID: US20150104457A1
- Status: Published application
- Kind: A1
- Application number: 14/396,689
- Filed: 2013-06-25
- Published: 2015-04-16
- Earliest claimed: 2012-06-25
- Assignees: Orega Biotech
- Applicants: Orega Biotech
- Inventors: Gilles Alberici; Jeremy Bastid; Armand Bensussan; Nathalie Bonnefoy; Jean-Francois Eliaou
- Web page: https://patentgrep.com/patent/US20150104457A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- G01N 33/57515: of the breast
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 15/09: Recombinant DNA-technology
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.

## Claims

### Claim 1

An isolated IL-17 antibody which binds, as a major epitope, an epitope consisting of a sequence of the human IL-17A as set forth in SEQ ID NO: 8.

### Claim 2 (depends on 1)

The antibody of claim 1 which comprises:
a Kabat heavy chain complementarity determining region-1 (VH-CDR1) amino acid sequence which is identical to the VH-CDR1 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 5;
a Kabat heavy chain complementarity determining region-2 (VH-CDR2) amino acid sequence which is identical to the VH-CDR2 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 5;
a Kabat heavy chain complementarity determining region-3 (VH-CDR3) amino acid sequence which is identical to the VH-CDR3 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 5;
a Kabat light chain complementarity determining region-1 (VL-CDR1) amino acid sequence which is identical to the VL-CDR3 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 4;
a Kabat light chain complementarity determining region-2 (VL-CDR2) amino acid sequence which is identical to the VL-CDR2 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 4; and
a Kabat light chain complementarity determining region-3 (VL-CDR3) amino acid sequence which is identical to the VL-CDR3 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 4.

### Claim 3 (depends on 2)

The antibody of claim 2 which comprises:
a VH region comprising the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 5; and
a VL region comprising the amino acid sequence as set forth in SEQ ID NO: 4.

### Claim 4 (depends on 1)

The antibody of claim 1 which comprises:
a Kabat heavy chain complementarity determining region-1 (VH-CDR1) amino acid sequence which is identical to the VH-CDR1 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 6;
a Kabat heavy chain complementarity determining region-2 (VH-CDR2) amino acid sequence which is identical to the VH-CDR2 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 6;
a Kabat heavy chain complementarity determining region-3 (VH-CDR3) amino acid sequence which is identical to the VH-CDR3 of the VH region comprising the amino acid sequence as set forth in SEQ ID NO: 6;
a Kabat light chain complementarity determining region-1 (VL-CDR1) amino acid sequence which is identical to the VL-CDR3 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 7;
a Kabat light chain complementarity determining region-2 (VL-CDR2) amino acid sequence which is identical to the VL-CDR2 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 7; and
a Kabat light chain complementarity determining region-3 (VL-CDR3) amino acid sequence which is identical to the VL-CDR3 of the VL region comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 5 (depends on 4)

The antibody of claim 4 which comprises:
a VH chain comprising the amino acid sequence as set forth in SEQ ID NO: 6; and
a VL chain comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 6 (depends on 1)

The antibody of claim 1, which comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.

### Claim 7 (depends on 1)

The antibody of claim 1, which comprises a heavy chain constant region or fragment thereof.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody is a chimeric antibody, a human or humanized antibody, and/or a monoclonal antibody.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody is an antagonist of IL-17 or wherein the antibody has neutralizing activity against IL-17.

### Claim 10 (depends on 1)

The antibody of claim 1, which is an antibody fragment directed against IL-17.

### Claim 11 (depends on 1)

An isolated nucleic acid comprising a sequence encoding the antibody of claim 1.

### Claim 12 (depends on 1)

A composition comprising an isolated nucleic acid sequence encoding a VL region and an isolated nucleic acid encoding a VH region of the antibody of claim 1.

### Claim 13 (depends on 11)

A vector comprising an isolated nucleic acid of claim 11.

### Claim 14 (depends on 11)

A host cell comprising an isolated nucleic acid sequence of claim 11.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method for diagnosing or treating a patient comprising the step of administering to the patient an antibody of claim 1.

### Claim 17 (depends on 1)

A method for treating a disease in a patient, wherein the disease is an autoimmune disease, a chronic inflammatory disease or cancer, the method comprising the step of administering to the patient an antibody of claim 1.

### Claim 18 (depends on 1)

A method for increasing effectiveness of a therapeutic agent in treatment of cancer in a patient, the method comprising the step administering to the patient an antibody of claim 1.

### Claim 19 (depends on 14, 23, 24)

A method for producing an antibody that specifically binds IL-17, comprising the steps of:
culturing a host cell of claim 14, 23 or 24 under conditions suitable for expressing the antibody, and
recovering the antibody.

### Claim 20 (depends on 7)

The antibody of claim 7 wherein the heavy chain constant region is human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgE or IgD.

### Claim 21 (depends on 10)

The antibody of claim 10 wherein the antibody fragment is selected from the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 22 (depends on 12)

A vector comprising an isolated nucleic acid of claim 12.

### Claim 23 (depends on 12)

A host cell comprising an isolated nucleic acid sequence of claim 12.

### Claim 24 (depends on 13)

A host cell comprising a vector of claim 13.

### Claim 25 (depends on 15)

A method for diagnosing or treating a patient comprising the step of administering to the patient a pharmaceutical composition of claim 15.

### Claim 26 (depends on 15)

A method for treating a disease in a patient, wherein the disease is an autoimmune disease, a chronic inflammatory disease or cancer, the method comprising the step of administering to the patient a pharmaceutical composition of claim 15.

### Claim 27 (depends on 15)

A method for increasing effectiveness of a therapeutic agent in treatment of cancer in a patient, the method comprising the step administering to the patient a pharmaceutical composition of claim 15.

### Claim 28 (depends on 1)

The antibody of claim 1 which further binds to SEQ ID NO: 9.

### Claim 29 (depends on 2)

The antibody of claim 2 wherein the Kabat heavy chain complementarity determining region-1 (VH-CDR1) amino acid sequence consists of SEQ ID NO: 15.

### Claim 30 (depends on 2)

The antibody of claim 2 wherein the Kabat heavy chain complementarity determining region-2 (VH-CDR2) amino acid sequence consists of SEQ ID NO: 16.

### Claim 31 (depends on 2)

The antibody of claim 2 wherein the Kabat light chain complementarity determining region-1 (VL-CDR1) amino acid sequence consists of SEQ ID NO: 18.

### Claim 32 (depends on 2)

The antibody of claim 2 wherein the Kabat light chain complementarity determining region-2 (VL-CDR2) amino acid sequence consists of SEQ ID NO: 19.

### Claim 33 (depends on 4)

The antibody of claim 4 wherein the Kabat heavy chain complementarity determining region-1 (VH-CDR1) amino acid sequence consists of SEQ ID NO: 21.

### Claim 34 (depends on 4)

The antibody of claim 4 wherein the Kabat heavy chain complementarity determining region-2 (VH-CDR2) amino acid sequence consists of SEQ ID NO: 22.

### Claim 35 (depends on 4)

The antibody of claim 4 wherein the Kabat light chain complementarity determining region-1 (VL-CDR1) amino acid sequence consists of SEQ ID NO: 24.

### Claim 36 (depends on 4)

The antibody of claim 4 wherein the Kabat light chain complementarity determining region-2 (VL-CDR2) amino acid sequence consists of SEQ ID NO: 25.
